03-14-2022 11:27 AM CET
Press release from Orion Market Research
The global post polycythemia vera myelofibrosis (PPV-MF) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Post-polycythemia vera myelofibrosis is a form of the myeloproliferative neoplasm and is also called chronic idiopathic myelofibrosis. It is a rare chronic blood cancer. People with myelofibrosis (MF) have a defect in their bone marrow that results in an abnormal production of blood cells which causes scar tissue to form. The major factor driving the growth of the market is the increasing prevalence of polycythemia vera (PV) across the globe.
According to the Leukemia & Lymphoma Society, PV is more prevalent among Jews of Eastern European descent than other Europeans or Asians. However, the incidence of PV is about 2.8 per 100,000 population of men and about 1.3 per 100,000 population of women of all races. Additionally, an estimated number of people in a population with PV is about 22 cases per 100,000 people. Furthermore, PV is mostly diagnosed at the average age of 60 to 65 years and it is uncommon in individuals younger than 30 years. Hence, the increasing prevalence of PV is driving the growth of the global post polycythemia vera myelofibrosis (PPV-MF) market.
To Request a Sample of our Report on Post Polycythemia Vera Myelofibrosis (PPV-MF) Market: https://www.omrglobal.com/request-sample/post-polycythemia-vera-myelofibrosis-ppv-mf-market